ArticleBritish journal of cancer2011

Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin.

E Giovannetti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.